Galapagos NV logo

GLPG

Galapagos NV

$38.92

Earnings Summary

Revenue
$119.27Mn
Net Profits
$-115.48Mn
Net Profit Margins
-96.83%

Highlights

Revenue:

Galapagos NV’s revenue jumped 12.12% since last year same period to $119.27Mn in the Q4 2019. On a quarterly growth basis, Galapagos NV has generated -81.19% fall in its revenue since last 3-months.

Net Profits:

Galapagos NV’s net profit fell -872.16% since last year same period to $-115.48Mn in the Q4 2019. On a quarterly growth basis, Galapagos NV has generated -131.97% fall in its net profits since last 3-months.

Net Profit Margins:

Galapagos NV’s net profit margin fell -788.72% since last year same period to -96.83% in the Q4 2019. On a quarterly growth basis, Galapagos NV has generated -269.93% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Galapagos NV post its latest quarter earnings

EPS Estimate Current Quarter
-1.08
EPS Estimate Current Year
-1.08

Highlights

EPS Estimate Current Quarter:

Galapagos NV’s earning per share (EPS) estimates for the current quarter stand at -1.08 - a 2.7% jump from last quarter’s estimates.

EPS Estimate Current Year:

Galapagos NV’s earning per share (EPS) estimates for the current year stand at -1.08.

Key Ratios

Key ratios of the Galapagos NV post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Galapagos NV’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2022. This indicates that the Galapagos NV has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-06-30
-0.3
-0.29
0.14%
2022-03-31
-0.68
-0.21
68.7%
2023-02-23
-1.08
0
100%

Company Information

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.

Organisation
Galapagos NV
Headquarters
Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
Employees
1357
Industry
Health Technology
CEO
Paul Stoffels

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*